New drug duo targets aggressive leukemia that has come back
NCT ID NCT06712121
Summary
This study is testing whether a combination of two chemotherapy drugs, decitabine and venetoclax, can help adults with a specific type of aggressive blood cancer (T-cell leukemia/lymphoma) that has returned or not responded to previous treatment. The goal is to see if this drug combination can put the cancer into remission and potentially allow patients to receive a stem cell transplant. The trial will enroll 28 adults in South Korea.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
NOT_YET_RECRUITINGSeongnam-si, 13620, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, 03080, South Korea
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.